ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 692

Correlation of Urinary Soluble CD163 Levels with Clinicopathological Features in Lupus Nephritis: Its Role as a Potential Biomarker

Shilpa Venkataraman1, Ankita Singh 2, Manjula Murari 3, Vinita Agrawal 2, Amita Aggarwal 3 and Rakesh Pandey 4, 1Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, 2Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, 3Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, 4Sanjay Gandhi Postgraduate Institute for Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biomarkers, biopsies and systemic lupus erythematosus (SLE), Lupus nephritis, Macrophage

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: SLE – Clinical Poster I: Epidemiology & Pathogenesis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Lupus nephritis (LN), is seen in 30-50% patients with SLE and 5-10% patients progress to end-stage renal disease. The clinical disease activity indices do not reliably predict the renal histological activity. Hence, biopsy is still the gold standard to help in treatment decisions and prognosis assessment.

Soluble CD163 (sCD163), receptor shed from the alternatively activated macrophage (M2) has been recently found to be a potential urinary biomarker of active LN. To explore further, we studied the urinary sCD163 levels and CD163 positive cells in renal biopsies and studied their correlation with histological features.

Methods: SLE patients undergoing renal biopsy for LN were enrolled. The clinical data regarding disease activity and other parameters was collected. Pre-biopsy urine sample was collected and cell free supernatant was stored at -80C till analysis. Urinary sCD163 (uCD163) was measured by ELISA and the values were normalized to urinary creatinine excretion. 10 healthy control (HC) urine samples were also tested for comparison. The renal biopsies were classified according to the ISN-RPS classification. Activity index (AI) and chronicity index (CI) were calculated using modified NIH scoring system. Immunohistochemistry (IHC) for CD163 positive macrophages was done.  Statistical analysis was done using SPSSv20.0

Results: Forty SLE patients with active LN were enrolled [37 females, median age 27 years (12-56)]. All patients had active disease [median SLEDAI 16 (6-43), renal SLEDAI 8 (4-16)]. Among 40 patients, 1 had class II LN, 11 had class III, 26 had class IV and 2 had class V nephritis. The median AI was 8 (1-15) and CI was 2 (0-8).

Urinary sCD163 levels were higher in proliferative LN as compared to healthy controls.[49.6 ug/mg of creatinine (3.6-451) versus  4.2 ug/mg of creatinine (0.7-12) in HC; p< 0.001] and  showed significant correlation with biopsy activity index (r=0.50; p-value < 0.001), presence and frequency of subendothelial hyaline deposits (r=0.39; p-value < 0.05) and karyorrhexis (r=0.42; p-value < 0.01). They also correlated with the percentage of glomeruli with endocapillary hypercellularity (r=0.39; p-value < 0.01). The average number of CD163 positive cells/glomerulus was 7.8 (0-18). The positive association of uCD163 with activity Index was supported by the localization of CD163+ macrophages in the areas of interstitial inflammation, tubulointerstitial damage and glomeruli with proliferative lesions (Figure 1).

Renal SLEDAI (r=0.46, p-value < 0.01), serum creatinine (r=0.531; p-value < 0.001) and serum total protein (r=-0.34; p-value< 0.05) significantly correlated with chronicity index.  The CD163 positive cells were seen along periglomerular fibrosis and around sclerosed glomeruli, though uCD163 levels did not correlate with chronicity index.

Conclusion: Urinary CD163 is a good marker of active LN and correlates with histological activity. CD163+ macrophages are localized to areas of activity as well as chronicity and may contribute to pathogenesis of LN.

Figure 1: CD163 positive cells in renal biopsies at different sites


Disclosure: S. Venkataraman, None; A. Singh, None; M. Murari, None; V. Agrawal, None; A. Aggarwal, None; R. Pandey, None.

To cite this abstract in AMA style:

Venkataraman S, Singh A, Murari M, Agrawal V, Aggarwal A, Pandey R. Correlation of Urinary Soluble CD163 Levels with Clinicopathological Features in Lupus Nephritis: Its Role as a Potential Biomarker [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/correlation-of-urinary-soluble-cd163-levels-with-clinicopathological-features-in-lupus-nephritis-its-role-as-a-potential-biomarker/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/correlation-of-urinary-soluble-cd163-levels-with-clinicopathological-features-in-lupus-nephritis-its-role-as-a-potential-biomarker/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology